Abstract
PUK5 - The Financial Impact of Introducing Darbepoetin Alfa (DA) as a New Long-Acting Erythropoiesis-Stimulating Agent Alternative for Non-Adherent Peritoneal Dialysis Patients in the Ministry of Health (MOH) Malaysia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
